keyword
MENU ▼
Read by QxMD icon Read
search

Cisplatin use in adjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/29217088/induction-cisplatin-docetaxel-followed-by-surgery-and-erlotinib-in-non-small-cell-lung-cancer
#1
Tina Cascone, Kathryn A Gold, Stephen G Swisher, Diane D Liu, Frank V Fossella, Boris Sepesi, Apar Pataer, Annikka Weissferdt, Neda Kalhor, Ara A Vaporciyan, Wayne L Hofstetter, Ignacio I Wistuba, John V Heymach, Edward S Kim, William N William
BACKGROUND: Data from meta-analyses support the use of induction or adjuvant platinum-based chemotherapy for locally advanced non-small cell lung cancers (NSCLCs). This phase 2 study assessed the role of induction cisplatin and docetaxel followed by surgery in patients with resectable stage I to III NSCLCs, followed by 12 months of adjuvant erlotinib. METHODS: Patients with resectable stage I to III NSCLCs received cisplatin 80 mg/m2, docetaxel 75 mg/m2 every 21 days for 3 cycles, followed by surgery, followed by adjuvant erlotinib for 12 months...
December 4, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29207134/novel-herbal-medicine-la16001-ameliorates-cisplatin-induced-anorexia
#2
Sang-Mi Woo, Kang Min Lee, Gyu Ri Lee, Ji Youn Park, Hee Jae Lee, Hyo-Jung Bahn, Hyun Seok Yoon, Jem Yung Kim, Young Cheol Shin, Sung-Gook Cho, Seong-Gyu Ko
Chemotherapy frequently causes anorexia in cancer patients, which has been associated with poor disease prognosis. Several therapeutic strategies for the treatment of chemotherapy‑induced anorexia are available; however, their adverse effects limit their clinical use. Herbal medicines have a long history of use for the treatment of various diseases, including cancer, and recent research has demonstrated their safety and efficacy. In the present study, combinations of herbal medicines were designed based on traditional Korean medicine, and their effects were investigated on chemotherapy‑induced anorexia...
November 28, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29188298/adjuvant-sandwich-chemotherapy-plus-radiotherapy-vs-adjuvant-chemotherapy-alone-for-locally-advanced-bladder-cancer-after-radical-cystectomy-a-randomized-phase-2-trial
#3
Mohamed S Zaghloul, John P Christodouleas, Andrew Smith, Ahmed Abdallah, Hany William, Hussein M Khaled, Wei-Ting Hwang, Brian C Baumann
Importance: Locoregional failure for patients with locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity and mortality. Adjuvant radiotherapy (RT) can decrease locoregional failure but has not been studied in the chemotherapy era. Objective: To investigate if adjuvant sequential RT plus chemotherapy can improve locoregional recurrence-free survival (LRFS) compared with adjuvant chemotherapy alone...
November 29, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/29177194/primary-upper-urinary-tract-small-cell-carcinoma-a-case-series-and-literature-review
#4
Patrick J Hensley, Amul A Bhalodi, Shubham Gupta
Background: Primary upper urinary tract small cell carcinoma (SCC) is exceedingly rare with < 30 cases reported in the literature. Little is known about the incidence, diagnosis, treatment, and outcomes in these patients. We present a series of three patients with primary upper tract SCC. Case Presentation: Patient 1 is an 89-year-old Caucasian male who presented with hydroureteronephrosis and a mass in the proximal right ureter. Biopsy revealed SCC. Without further intervention, the patient died 2 months after his diagnosis...
2017: Journal of Endourology Case Reports
https://www.readbyqxmd.com/read/29157115/subgroup-analysis-based-on-prognostic-and-predictive-gene-signatures-for-adjuvant-chemotherapy-in-early-stage-non-small-cell-lung-cancer-patients
#5
Hojin Moon, Yuan Zhao, Dustin Pluta, Hongshik Ahn
In treating patients diagnosed with early Stage I non-small-cell lung cancer (NSCLC), doctors must choose surgery alone, Adjuvant Cisplatin-Based Chemotherapy (ACT) alone or both. For patients with resected stages IB to IIIA, clinical trials have shown a survival advantage from 4-15% with the adoption of ACT. However, due to the inherent toxicity of chemotherapy, it is necessary for doctors to identify patients whose chance of success with ACT is sufficient to justify the risks. This research seeks to use gene expression profiling in the development of a statistical decision-making algorithm to identify patients whose survival rates will improve from ACT treatment...
November 20, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/29138580/s100a16-a-promising-candidate-as-a-prognostic-marker-for-platinum-based-adjuvant-chemotherapy-in-resected-lung-adenocarcinoma
#6
Ken Katono, Yuichi Sato, Makoto Kobayashi, Ryo Nagashio, Shinichiro Ryuge, Satoshi Igawa, Masaaki Ichinoe, Yoshiki Murakumo, Makoto Saegusa, Noriyuki Masuda
Purpose: Although cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying biomarkers is important for selecting subgroups of patients who may show improved survival with platinum-based adjuvant chemotherapy. S100A16 is thought to play key roles during different steps of tumor progression. The aim of this study was to evaluate the use of S100A16 expression as a prognostic marker in patients with completely resected lung adenocarcinoma receiving platinum-based adjuvant chemotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29129443/adjuvant-chemotherapy-with-or-without-bevacizumab-in-patients-with-resected-non-small-cell-lung-cancer-e1505-an-open-label-multicentre-randomised-phase-3-trial
#7
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, William J Tester, David R Gandara, Stephen L Graziano, Alex A Adjei, Natasha B Leighl, Seena C Aisner, Jan M Rothman, Jyoti D Patel, Mark D Sborov, Sean R McDermott, Roman Perez-Soler, Anne M Traynor, Charles Butts, Tracey Evans, Atif Shafqat, Andrew E Chapman, Samer S Kasbari, Leora Horn, Suresh S Ramalingam, Joan H Schiller
BACKGROUND: Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. METHODS: We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29113380/adjuvant-chemotherapy-for-muscle-invasive-bladder-cancer-a-systematic-review-and-network-meta-analysis-of-randomized-clinical-trials
#8
Hyung Suk Kim, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
Although adjuvant chemotherapy (ACH) is widely used in clinical practice for the management of muscle-invasive bladder cancer (MIBC), a consensus has yet to be established on which ACH regimen is the most effective for improving postoperative survival. In this study, we aimed to systematically assess the optimal ACH regimen for improving survival outcomes in patients treated with radical cystectomy (RC) for MIBC. A comprehensive literature search was conducted in the PubMed, Embase, and the Cochrane Library databases for all articles published until December 2016 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29103747/the-clinicopathological-spectrum-of-olfactory-neuroblastoma-and-sinonasal-neuroendocrine-neoplasms-refinements-in-diagnostic-criteria-and-impact-of-multimodal-treatments-on-survival
#9
Mario Turri-Zanoni, Roberta Maragliano, Paolo Battaglia, Marta Giovannardi, Paolo Antognoni, Davide Lombardi, Maria Laura Morassi, Ernesto Pasquini, Paolo Tarchini, Sofia Asioli, Maria Pia Foschini, Fausto Sessa, Piero Nicolai, Paolo Castelnuovo, Stefano La Rosa
OBJECTIVES: To provide a comprehensive review of the clinical and histopathological features of olfactory neuroblastoma (ONB) and other sinonasal neuroendocrine neoplasms (NENs), in order to refine diagnostic criteria, analyze treatment outcomes, and identify prognostic factors. METHODS: Data from an Italian multi-institutional database were analyzed. Patients were treated surgically via a minimally-invasive endoscopic approach followed by adjuvant radiotherapy or radiochemotherapy...
November 2017: Oral Oncology
https://www.readbyqxmd.com/read/29049188/incidence-of-venous-thromboembolism-following-the-neoadjuvant-chemotherapy-regimen-for-epithelial-type-of-ovarian-cancer
#10
Devendra Manik Chavan, Zhen Huang, Kun Song, Leela Rani Haricharan Parimi, Xing Sheng Yang, Xiangning Zhang, Peishu Liu, Jie Jiang, Youzhong Zhang, Beihua Kong, Li Li
This study aims to analyze the risk of venous thromboembolism (VTE) in patients receiving neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC).A retrospective audit was conducted examining 147 patients treated for EOC. Surgical treatment with curative intent, with or without NACT and adjuvant chemotherapy, is the treatment approach, which was modified according to the patient's condition. The incidence of VTE with the most commonly used chemotherapy regimen, carboplatin, cisplatin, paclitaxel, docetaxel, and others were evaluated...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29047418/primary-small-cell-carcinoma-of-the-breast-a-case-report
#11
Iman Abou Dalle, Jaber Abbas, Fouad Boulos, Ziad Salem, Hazem I Assi
BACKGROUND: Neuroendocrine breast cancer is a rare entity that was defined in 2003 by the World Health Organization as a separate breast cancer subtype. The diagnosis of neuroendocrine breast cancer requires the presence of neuroendocrine features in at least 50% of malignant cells, the exclusion of non-mammary primary tumors, as well as the presence of an in situ component in breast histology. The treatment and prognosis of neuroendocrine breast cancer are still not well established...
October 19, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29017913/the-use-of-natural-compounds-for-the-targeting-and-chemoprevention-of-ovarian-cancer
#12
Francesca Pistollato, Ruben Calderón Iglesias, Roberto Ruiz, Silvia Aparicio, Jorge Crespo, Luis Dzul Lopez, Francesca Giampieri, Maurizio Battino
Among gynaecological cancers, ovarian cancer represents the leading cause of death in women. Current treatment for ovarian cancer entails surgery followed by combined chemotherapy with platinum and taxane, which are associated, particularly cisplatin, with severe side effects. While this treatment approach appears to be initially effective in a high number of patients, nearly 70% of them suffer a relapse within a few months after initial treatment. Therefore, more effective and better-tolerated treatment options are clearly needed...
October 7, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28975094/ameliorative-effect-of-lycopene-effect-on-cisplatin-induced-nephropathy-in-patient
#13
Leila Mahmoodnia, Keivan Mohammadi, Rohollah Masumi
BACKGROUND: Nephrotoxicity is one of the most important limitations of cisplatin-based chemotherapies which associated with many complications and high mortality rate. OBJECTIVES: To investigate the effect of lycopene on cisplatin-induced nephrotoxicity in patients with cancer. PATIENTS AND METHODS: In this double-blind, randomized clinical trial, 120 patients were randomly assigned to two groups, case (treated with lycopene + standard regimen of kidney injury prevention) and control (treated with only the standard regimen of kidney injury prevention)...
July 2017: Journal of Nephropathology
https://www.readbyqxmd.com/read/28971956/tap73-is-a-marker-of-glutamine-addiction-in-medulloblastoma
#14
Maria Victoria Niklison-Chirou, Ida Erngren, Mikael Engskog, Jakob Haglöf, Daniel Picard, Marc Remke, Phelim Hugh Redmond McPolin, Matthew Selby, Daniel Williamson, Steven C Clifford, David Michod, Michalis Hadjiandreou, Torbjörn Arvidsson, Curt Pettersson, Gerry Melino, Silvia Marino
Medulloblastoma is the most common solid primary brain tumor in children. Remarkable advancements in the understanding of the genetic and epigenetic basis of these tumors have informed their recent molecular classification. However, the genotype/phenotype correlation of the subgroups remains largely uncharacterized. In particular, the metabolic phenotype is of great interest because of its druggability, which could lead to the development of novel and more tailored therapies for a subset of medulloblastoma...
September 1, 2017: Genes & Development
https://www.readbyqxmd.com/read/28954697/cycles-of-cisplatin-and-etoposide-affect-treatment-outcomes-in-patients-with-figo-stage-i-ii-small-cell-neuroendocrine-carcinoma-of-the-cervix
#15
Xuan Pei, Libing Xiang, Shuang Ye, Tiancong He, Yufan Cheng, Wentao Yang, Xiaohua Wu, Huijuan Yang
OBJECTIVE: This study sought to explore the outcomes and prognostic factors of patients with small cell neuroendocrine carcinoma of the cervix (SCNEC) and to determine the effects of adjuvant treatment on survival in patients with FIGO stage I-II SCNEC after radical surgery. METHODS: A single-institution retrospective analysis was performed in 92 patients who underwent radical surgery for SCNEC. All clinicopathological variables and treatment strategies were reviewed...
September 24, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28944145/rare-case-of-ameloblastoma-with-pulmonary-metastases
#16
Ivan Valkadinov, Nikolay Conev, Dian Dzhenkov, Ivan Donev
Ameloblastoma is a rare low-grade odontogenic tumor of epithelial origin. The World Health Organization (WHO) has defined malignant ameloblastoma (MA) as a histologically benign-appearing ameloblastoma that has metastasized. Treatment of the primary ameloblastoma usually consists of radical excision of the tumor and adjuvant radiotherapy. Chemotherapy should be used to treat metastases due to its indolent clinical course. Presented here is the case of a 43-year-old woman who was admitted to a hospital in 2006 with a large mass involving the neck and left mandible...
August 2017: Intractable & Rare Diseases Research
https://www.readbyqxmd.com/read/28927134/primary-mucinous-adenocarcinoma-of-the-lung-a-case-report-and-review-of-the-literature
#17
Yan Liu, He-Long Zhang, Jia-Zhuan Mei, Yan-Wei Guo, Rui-Jun Li, Si-Dong Wei, Fu Tian, Lu Yang, Hui Wang
Mucinous adenocarcinoma is an unusual histological type of lung cancer, and its clinicopathological feature is distinctive from that of other histopathological types of lung adenocarcinoma. Mucinous adenocarcinoma has a mucus-producing function, which explains its name. The present study reports a rare case of a mucus-producing adenocarcinoma of the lung. A 60-year-old Chinese female patient was diagnosed with mucinous adenocarcinoma of the lung, which manifested as respiratory symptoms, including fever, cough and expectoration...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927101/effects-of-p38mapk-mediated-excision-repair-cross-complementation-1-expression-on-prognosis-of-patients-with-non-small-cell-lung-cancer
#18
Dan He, Xiaomei Ma, Zhenhua Wu, Yang Wang, Shuyuan Zhao, Feng Han, Wei Sun
The present study aimed to investigate the effects of excision repair cross-complementation 1 (ERCC1) expression on the prognosis of patients with non-small cell lung cancer (NSCLC). A total of 140 patients with NSCLC who underwent radical resection were included. Immunohistochemical staining was performed on the tissue specimens obtained from patients and correlation analysis was used to determine the association between ERCC1 expression and clinicopathological characteristics. Cell proliferation was assessed using an MTT assay...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28915900/a-randomized-phase-ii-study-to-assess-the-effect-of-adjuvant-immunotherapy-using-%C3%AE-galcer-pulsed-dendritic-cells-in-the-patients-with-completely-resected-stage-ii-iiia-non-small-cell-lung-cancer-study-protocol-for-a-randomized-controlled-trial
#19
Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M Saito, Suminobu Ito
BACKGROUND: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only)...
September 15, 2017: Trials
https://www.readbyqxmd.com/read/28898353/in-vivo-chemotherapeutic-insight-of-a-novel-isocoumarin-3-hexyl-5-7-dimethoxy-isochromen-1-one-genotoxicity-cell-death-induction-leukometry-and-phagocytic-evaluation
#20
Flávio Henrique Souza de Araújo, Débora Rojas de Figueiredo, Sarah Alves Auharek, João Renato Pesarini, Alisson Meza, Roberto da Silva Gomes, Antônio Carlos Duenhas Monreal, Andréia Conceição Milan Brochado Antoniolli-Silva, Dênis Pires de Lima, Candida Aparecida Leite Kassuya, Adilson Beatriz, Rodrigo Juliano Oliveira
Chemotherapy is one of the major approaches for the treatment of cancer. Therefore, the development of new chemotherapy drugs is an important aspect of medicinal chemistry. Chemotherapeutic agents include isocoumarins, which are privileged structures with potential antitumoral activity. Herein, a new 3-substituted isocoumarin was synthesized from 2-iodo-3,5-dimethoxy-benzoic acid and oct-1-yne in a cross-coupling Sonogashira reaction followed by a copper iodide-catalyzed intramolecular cyclization as key step using MeOH/Et3N as the solvent system...
July 2017: Genetics and Molecular Biology
keyword
keyword
52196
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"